Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition

Radiation Oncology

Volumn 1, Issue 1, 2006, Pages

  Flatmark, Kjersti ^a,b   Nome, Ragnhild V ^a   Folkvord, Sigurd ^a   Bratland, Åse ^a,b   Rasmussen, Heidi ^a   Ellefsen, Mali Strand ^b   Fodstad, Oslash ystein ^a   Ree, Anne Hansen ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; RADIOSENSITIZING AGENT;

ARTICLE; CELL CYCLE; CHEMISTRY; CHROMATIN; COLORECTAL TUMOR; DNA DAMAGE; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; MUTATION; PHENOTYPE; RADIATION EXPOSURE; RADIOTHERAPY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CELL CYCLE; CELL LINE, TUMOR; CHROMATIN; COLORECTAL NEOPLASMS; DNA DAMAGE; GENES, P53; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; MUTATION; PHENOTYPE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY;

EID: 33847653614     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-1-25     Document Type: Article

References (47)

1. Glimelius B Gronberg H Jarhult J Wallgren A Cavallin-Stahl E A systematic overview of radiation therapy effects in rectal cancer Acta Oncol 2003 42 476-492 10.1080/02841860310012301 14596508
2. Sauer R Becker H Hohenberger W Rodel C Wittekind C Fietkau R Martus P Tschmelitsch J Hager E Hess CF Karstens JH Liersch T Schidberger H Raab R Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 2004 351 1731-1740 10.1056/NEJMoa040694 15496622
3. Milas L Mason KA Liao Z Ang KK Chemoradiotherapy: Emerging treatment improvement strategies Head Neck 2003 25 152-167 10.1002/hed.10232 12509799
4. Kastan MB Bartek J Cell-cycle checkpoints and cancer Nature 2004 432 316-323 10.1038/nature03097 15549093
5. Fei P El-Deiry WS P53 and radiation responses Oncogene 2003 22 5774-5783 10.1038/sj.onc.1206677 12947385
6. Barr FA Sillje HHW Nigg EA Polo-like kinases and the orchestration of cell division Nat Rev Mol Cell Biol 2004 5 429-440 10.1038/nrm1401 15173822
7. Nome RV Bratland Å Harman G Fodstad Ø Andersson Y Ree AH Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death Mol Cancer Ther 2005 4 1231-1238 10.1158/1535-7163.MCT-04-0304 16093439
8. Ree AH Bratland Å Nome RV Stokke T Fodstad Ø Repression mRNA for the PLK cell cycle gene after DNA damage requires BRCA1 Oncogene 2003 22 8952-8955 10.1038/sj.onc.1207000 14654792
9. Ree AH Bratland Å Nome RV Stokke T Fodstad Ø Andersson Y Inhibitory targeting of checkpoint kinase signaling impairs radiation-induced cell cycle gene regulation: A therapeutic strategy in tumor cell radiosensitization? Radiother Oncol 2004 72 305-310 10.1016/ j.radonc.2004.07.002 15450729
10. Zhou BBS Bartek J Targeting the checkpoint kinases: Chemosensitization versus chemoprotection Nat Rev Cancer 2004 4 1-10 10.1038/nrc1296
11. Deutsch E Soria JC Armand JP New concepts for phase I trials: Evaluating new drugs combined with radiation therapy Nat Clin Pract Oncol 2005 2 456-465 10.1038/ncponc0295 16264990
12. Choy H Taxanes in combined modality therapy for solid tumors Crit Rev Oncol Hematol 2001 37 237-247 11248579
13. Johnstone RW Licht JD Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003 4 13-18 10.1016/ S1535-6108(03)00165-X 12892709
14. Beamish H Warrener R Gabrielli BG Analysis of checkpoint responses to histone deacetylase inhibitors Methods Mol Biol 2004 281 245-259 15220534
15. Kelly WK Marks PA Drug insight: Histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid Nat Clin Pract Oncol 2005 2 150-157 10.1038/ncponc0106 16264908
16. Iacopetta B TP53 mutation in colorectal cancer Hum Mutat 2003 21 271-276 10.1002/humu.10175 12619112
17. Tankel K Hay J Ma R Toy E Larsson S MacFarlane J Short-course preoperative radiation therapy for operable rectal cancer Am J Surg 2002 183 509-511 10.1016/S0002-9610(02)00832-2 12034382
18. Flatmark K Maelandsmo GM Martinsen M Rasmussen H Fodstad Ø Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice Eur J Cancer 2004 40 1593-1598 10.1016/j.ejca.2004.02.023 15196545
19. DeMasters GA Gupta MS Jones KR Cabot M Wang H Gennings C Park M Bratland A Ree AH Gewirtz DA Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the vitamin D(3) analog EB 1089 J Steroid Biochem Mol Biol 2004 92 365-374 10.1016/j.jsbmb.2004.07.011 15698541
20. Atadja P Gao L Kwon P Trogani N Walker H Hsu M Yeleswarapu L Chandramouli N Perez L Versace R Wu A Sambucetti L Lassota P Cohen D Bair K Wood A Remiszewski S Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824 Cancer Res 2004 64 689-695 10.1158/0008-5472.CAN-03-2043 14744786
21. Bali P Pranpat M Swaby R Fiskus W Yamaguchi H Balasis M Rocha K Wang HG Richon V Bhalla K Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2 Clin Cancer Res 2005 11 6382-6389 10.1158/1078-0432.CCR-05-0344 16144943
22. Blagosklonny MV Robey R Sackett DL Du L Traganos F Darzynkiewicz Z Fojo T Bates SE Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity Mol Cancer Ther 2002 1 937-941 12481415
23. Takai N Desmond JC Kumagai T Gui D Said JW Whittaker S Miyakawa I Koeffler HP Histone deacetylase inhibitors have profound antigrowth activity in endometrial cancer cells Clin Cancer Res 2004 10 1141-1149 10.1158/1078-0432.CCR-03-0100 14871994
24. The International Agency for Research on Cancer's TP53 Mutation Database http://www-p53.iarc.fr
25. Russo A Bazan V Iacopetta B Kerr D Soussi T Gebbia N The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment J Clin Oncol 2005 23 7518-7528 10.1200/JCO.2005.00.471 16172461
26. Komatsu N Kawamata N Takeuchi S Yin D Chien W Miller CW Koeffler HP SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells Oncol Rep 2006 15 187-191 16328054
27. Zhang Y Jung M Dritschilo A Jung M Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors Radiat Res 2004 161 667-674 10.1667/RR3192 15161353
28. Ju R Muller MT Histone deacetylase inhibitors activate p21[WAF1] expression via ATM Cancer Res 2003 63 2891-2897 12782595
29. Gui CY Ngo L Xu WS Richon VM Marks PA Histone deacetylase (HDAC) inhibitor activation of p21[WAF1] involves changes in promoter-associated proteins, including HDAC1 Proc Natl Acad Sci USA 2004 101 1241-1246 337037 14734806 10.1073/pnas.0307708100
30. Alao JP Lam EWF Ali S Buluwela L Bordogna W Lockey P Varshochi R Stavropoulou AV Coombes RC Vigushin DM Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines Clin Cancer Res 2004 10 8094-8104 10.1158/ 1078-0432.CCR-04-1023 15585645
31. Crawford DF Piwnica-Worms H The G(2) DNA damage checkpoint delays expression of genes encoding mitotic regulators J Biol Chem 2001 276 37166-37177 10.1074/jbc.M103414200 11483598
32. Kim MS Blake M Baek JH Kohlhagen G Pommier Y Carrier F Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA Cancer Res 2003 63 7291-7300 14612526
33. Maggio SC Rosato RR Kramer LB Dai Y Rahmani M Paik DS Czarnik AC Payne SG Spiegel S Grant S The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells Cancer Res 2004 64 2590-2600 10.1158/0008-5472.CAN-03-2631 15059916
34. Wang XF Qian DZ Ren M Kato Y Wei Y Zhang L Fansler Z Clark D Nakanishi O Pili R Epigenetic modulation of retinoic acid receptor [beta]2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma Clin Cancer Res 2005 11 3535-3542 10.1158/1078-0432.CCR-04-1092 15867257
35. Camphausen K Burgan W Cerra M Oswald KA Trepel JB Lee MJ Tofilon PJ Enhanced radiation-induced cell killing and prolongation of [gamma]H2AX foci expression by the histone deacetylase inhibitor MS-275 Cancer Res 2004 64 316-321 10.1158/0008-5472.CAN-03-2630 14729640
36. Camphausen K Cerna D Scott T Sproull M Burgan WE Cerra MA Fine H Tofilon PJ Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid Int J Cancer 2005 114 380-386 10.1002/ijc.20774 15578701
37. Camphausen K Scott T Sproull M Tofilon PJ Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation Clin Cancer Res 2004 10 6066-6071 10.1158/1078-0432.CCR-04-0537 15447991
38. Chinnaiyan P Vallabhaneni G Armstrong E Huang SM Harari PM Modulation of radiation response by histone deacetylase inhibition Int J Radiat Oncol Biol Phys 2005 62 223-229 10.1016/j.ijrobp.2004.12.088 15850925
39. Munshi A Kurland JF Nishikawa T Tanaka T Hobbs ML Tucker SL Ismail S Stevens C Meyn RE Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity Clin Cancer Res 2005 11 4912-4922 10.1158/1078-0432.CCR-04-2088 16000590
40. Zhang Y Adachi M Zhao X Kawamura R Imai K Histone deacetylase inhibitors FK228,
41. Chung YL Wang AJ Yao LF Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy Mol Cancer Ther 2004 3 317-325 15026552
42. Onyia JE Galvin RJS Ma YL Halladay DL Miles RR Yang X Fuson T Cain RL Zeng QQ Chandrasekhar S Emkey R Xu Y Thirunavukkarasu K Bryant HU Martin TJ Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption J Pharmacol Exp Ther 2004 309 369-379 10.1124/jpet.103.057893 14718597
43. Glaser KB Li J Pease LJ Staver MJ Marcotte PA Guo J Frey RR Garland RB Heyman HR Wada CK Vasudevan A Michaelides MR Davidsen SK Curtin ML Differential protein acetylation induced by novel histone deacetylase inhibitors Biochem Biophys Res Commun 2004 325 683-690 10.1016/ j.bbrc.2004.10.082 15541343
44. Glaser KB Staver MJ Waring JF Stender J Ulrich RG Davidsen SK Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common set produced by HDAC inhibition in T24 and MDA carcinoma cell lines Mol Cancer Ther 2003 2 151-163 12589032
45. Kelly WK O'Connor OA Krug LM Chiao JH Heaney M Curley T MacGregore-Cortelli B Tong W Secrist JP Schwartz L Richardson S Chu E Olgac S Marks PA Scher H Richon VM Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J Clin Oncol 2005 23 3923-3931 10.1200/JCO.2005.14.167 15897550
46. O'Connor OA Heaney ML Schwartz L Richardson S Willim R MacGregor-Cortelli B Curly T Moskowitz C Portlock C Horwitz S Zelenetz AD Frankel S Richon V Marks P Kelly WK Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies J Clin Oncol 2006 24 166-173 10.1200/ JCO.2005.01.9679 16330674
47. Ryan QC Headlee D Acharya M Sparreboom A Trepel JB Ye J Figg WD Hwang K Chung EJ Murgo A Melillo G Elsayed Y Monga M Kalnitskiy M Zwiebel J Sausville EA Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma J Clin Oncol 2005 23 3912-3922 10.1200/ JCO.2005.02.188 15851766